Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mNGF for cognitive decline in cerebral small vessel disease
ChiCTR1900021143Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of mouse nerve growth factor in Cerebral Small Vessel Disease (CSVD), vascular cognitive disorder (VCD) and Dementia (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: ADAS-cog at 3 months. Started Sep 2018; status: recruiting.
02
Drugs
mouse nerve growth factor
03
Conditions
Cerebral Small Vessel Disease (CSVD)vascular cognitive disorder (VCD)Dementia
Beyond the preview
Go deeper on ChiCTR1900021143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021143.